HC Wainwright & Co. Maintains Buy on Oruka Therapeutics, Raises Price Target to $120

Benzinga Newsdesk www.benzinga.com Positive 56.8%

Neg 0% Neu 0% Pos 56.8%

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Oruka Therapeutics (NASDAQ:ORKA) with a Buy and raises the price target from $75 to $120.